Literature DB >> 9723046

Treatment of facial telangiectases with the diode-pumped frequency-doubled Q-switched Nd:YAG laser.

D J Goldberg1, J G Meine.   

Abstract

BACKGROUND: Many individuals develop telangiectases on the face as they mature. The causative factors are numerous. Telangiectases are cosmetically concerning for many of those who are affected. Because of the ability to selectively target vessels, lasers have recently become the focus for treating small facial telangiectases.
OBJECTIVE: The purpose of this study was to evaluate the efficacy of the diode-pumped frequency-doubled Q-switched neodymium: ytterium-aluminum-garnet (FD QSNd:YAG) laser (532 nm) for the treatment of telangiectases on the face.
METHODS: The diode-pumped FD QSNd:YAG laser (532 nm, 400-micron spot size, 24-msec pulse train) was used to treat telangiectases on the face of 30 adult subjects. Patients were treated once, and clinical improvement and potential adverse effects were assessed at 4 and 8 weeks after treatment.
RESULTS: One session of diode-pumped FD QSNd:YAG laser treatment either improved or totally cleared all treated facial telangiectases.
CONCLUSION: The diode-pumped FD QSNd:YAG laser is effective for treating small facial telangiectases. An advantage of this laser is that it does not produce postoperative purpura.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723046     DOI: 10.1111/j.1524-4725.1998.tb04259.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Laser and light-based therapies in the management of rosacea: an updated systematic review.

Authors:  Husein Husein-ElAhmed; Martin Steinhoff
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

2.  980 nm diode lasers in oral and facial practice: current state of the science and art.

Authors:  Apollonia Desiate; Stefania Cantore; Domenica Tullo; Giovanni Profeta; Felice Roberto Grassi; Andrea Ballini
Journal:  Int J Med Sci       Date:  2009-11-24       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.